Creatine for Parkinson's disease
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Parkinson's disease is one of the most common neurodegenerative disorders and mitochondrial dysfunction plays an important role in its pathogenesis. Creatine is effective in improving mitochondrial function. It may therefore be useful for slowing the progression of Parkinson's disease. OBJECTIVES: To assess the efficacy and safety of creatine used alone or as an adjuvant treatment for Parkinson's disease. SEARCH METHODS: We searched the Cochrane Movement Disorders Group Trials Register, CENTRAL (The Cochrane Library 2013, November Issue 4), MEDLINE (January 1966 to 10 November 2013), EMBASE (1974 to 10 November 2013) and two Chinese databases. We searched ongoing trials registers and conference proceedings, checked reference lists and contacted authors of included trials. SELECTION CRITERIA: Randomized controlled trials (RCTs) comparing creatine versus placebo for Parkinson's disease. DATA COLLECTION AND ANALYSIS: Two review authors independently selected the trials for inclusion, assessed trial quality and extracted data. MAIN RESULTS: We included two RCTs with a total of 194 patients. Both trials compared creatine with placebo for Parkinson's disease and both had methodological limitations. There was no clear evidence of an effect on motor function (MD -0.26; 95% confidence interval (CI) -4.39 to 3.88, low quality evidence), activities of daily living (MD 0.37; 95% CI -1.28 to 2.02, low quality evidence) or quality of life after one or two years of treatment. One trial reported serious adverse events that were not attributed to creatine. Also, one trial observed higher rates of gastrointestinal effects at two years follow-up. AUTHORS' CONCLUSIONS: The evidence base on the effects of creatine in Parkinson's disease is limited by risk of bias, small sample sizes and short duration of the eligible trials. It does not provide a reliable basis on which treatment decisions can be made. Future well-designed RCTs with larger sample size and long-term follow-up are needed to assess creatine for Parkinson's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondria take center stage in aging and neurodegeneration
Beal, M. F. (2005) · Annals of Neurology · doi:10.1002/ana.20624 · Cited by 957
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
Direct antioxidant properties of creatine
Lawler, J. M., Barnes, W. S., Wu, G., Song, W., & Demaree, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6164 · Cited by 448
Boutron, I., Tubach, F., Giraudeau, B., & Ravaud, P. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2003.12.010 · Cited by 300
Sestili, P., Martinelli, C., Bravi, G., Piccoli, G., Curci, R., Battistelli, M., Falcieri, E., Agostini, D., Gioacchini, A. M., & Stocchi, V. (2006) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.10.035 · Cited by 220
Long-term creatine supplementation is safe in aged patients with Parkinson disease
Bender, A., Samtleben, W., Elstner, M., & Klopstock, T. (2008) · Nutrition Research · doi:10.1016/j.nutres.2008.01.001 · Cited by 79
Cited by
Alirezaei, Z., Pourhanifeh, M. H., Borran, S., Nejati, M., Mirzaei, H., & Hamblin, M. R. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01698-3 · Cited by 142
“The clinical manifestation of PD is principally motor dysfunction including involuntary tremor, bradykinesia, and rigidity [40].”
BackgroundCreatine for neuroprotection in neurodegenerative disease: end of story?
Bender, A., & Klopstock, T. (2016) · Amino Acids · doi:10.1007/s00726-015-2165-0 · Cited by 96
“A meta-analysis of the 194 patients of the two pilot or Phase II trials revealed no effect on either motor function or activities of daily living (ADL) but concluded that data was insufficient to draw a firm conclusion (Xiao et al. 2014).”
BackgroundCreatine and creatine forms intended for sports nutrition
Andres, S., Ziegenhagen, R., Trefflich, I., Pevny, S., Schultrich, K., Braun, H., Schänzer, W., Hirsch‐Ernst, K. I., Schäfer, B., & Lampen, A. (2017) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201600772 · Cited by 54
de Guingand, D. L., Palmer, K. R., Bilardi, J. E., & Ellery, S. J. (2020) · Midwifery · doi:10.1016/j.midw.2019.102599 · Cited by 15
Metadata
- Authors
- Xiao, Y., Luo, M., Luo, H., & Wang, J.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Wiley
- Published
- 2014-06-17
- Volume
- 2014
- Issue
- 6
- Pages
- CD009646-CD009646
- ISSN
- 1361-6137 (ISSN-L)
- 1465-1858
- OpenAlex
- W1909668357
- Cited by
- 18
- References
- 6
- FWCI
- 1.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Creatine for Parkinson's disease. https://app.cochat.ai/papers/10.1002/14651858.cd009646.pub2
- The paper
- Xiao, Y., Luo, M., Luo, H., & Wang, J. (2014). Creatine for Parkinson's disease. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd009646.pub2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.